Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40013348
Localisation
United Kingdom
Europe
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
SME
Dernière mise à jour
07/08/2025
Statut
Classification
1.5°C
Année cible
FY2030
Statut
Targets set
Classification
1.5°C
Année cible
FY2050
This target was approved using a streamlined target validation route exclusive to small and medium-sized enterprises (SMEs). https://docs.sbtiservices.com/resources/FAQsforSMEs.pdf Costello Medical commits to reduce scope 1 and scope 2 GHG emissions 42 % by FY2030 from a FY2023 base year, and to measure and reduce its scope 3 emissions. Costello Medical commits to reach net-zero latest by FY2050. As part of this, it commits to reduce absolute scope 1, 2 and 3 GHG emissions 90% by FY2050 from a FY2022 base year.
Statut
Targets setAnnée cible
FY2050
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
Source : Science Based Targets initiative | Données publiques